The Nuance in mTNBC | Part 2: The...

The Nuance in mTNBC | Part 2: The Patient the Trial Did Not Enroll

FLASCO OncoPod by Florida Society of Clinical Oncology
S1 · E34
Oct 28, 2026
15:59

Episode notes

How should clinicians approach metastatic triple-negative breast cancer (mTNBC) when a patient's treatment history does not align with the populations studied in clinical trials? In this episode of The Nuance in mTNBC, Dr. Edgardo Santos and Dr. Victoria Rizk explore the challenges of managing patients who experience recurrence following neoadjuvant immunotherapy and chemotherapy.

Through case-based discussion and insights from a FLASCO clinician survey, faculty examine the significance of treatment-free intervals, prior immunotherapy exposure, germline BRCA mutations, and the evolving first-line treatment landscape. The conversation also addresses the limitations of available clinical evidence, considerations for immunotherapy rechallenge, and individualized treatment strategies for patients with comorbidities, reduced performance status, or preferences that may limit therapeutic options.

This content has been created independently and solely by FLASCO. FLASCO would like to recognize our Elite Sponsor, Gilead Sciences, Inc.

Keywords

oncology
cancer
breastcancer
mTNBC